慢加急性肝衰竭预后标志物的研究现状  

Current status of research on the prognostic markers for acute-on-chronic liver failure

作　　者：李健 杜亚秋 李德钊 季慧范[1] 张成港 刘庆夏 郭晓林[1] LI Jian;DU Yaqiu;LI Dezhao;JI Huifan;ZHANG Chenggang;LIU Qingxia;GUO Xiaolin(Department of Hepatology,The First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院肝胆胰内科,长春130021

出　　处：《临床肝胆病杂志》2021年第11期2701-2705,共5页Journal of Clinical Hepatology

基　　金：国家重点研发计划“精准医学研究”专项(2017YFC0908104)。

摘　　要：慢加急性肝衰竭是一种以多器官功能衰竭、短期病死率高为主要特点的综合病症,是重症肝病领域的研究热点,故早期和准确的进行危险分层、及时加强干预,对切实改善预后具有重要意义。归纳总结了近年来涌现的评估ACLF患者预后的血清生物学标志物,认为新型血清标志物在ACLF患者的预后评估上具有重要指导意义。Acute-on-chronic liver failure(ACLF)is a syndrome characterized by multiple organ failure and high short-term mortality rate,and it has always been a research hotspot in the field of severe liver diseases.Therefore,early and accurate risk stratification and timely intervention are of great significance to improve prognosis.This article summarizes the serum biomarkers identified in recent years for evaluating the prognosis of patients with ACLF,and it is pointed out that new serum biomarkers have an important guiding significance in the prognostic evaluation of ACLF patients.

关 键 词：慢加急性肝功能衰竭 预后 生物标记 

分 类 号：R575.3[医药卫生—消化系统]